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Abstract
Background: Prostate cancer (PC) is one of the most commonly treated cancer entities with radiation therapy (RT).
Risk group-adapted treatment and avoidance of unnecessary toxicities relies primarily on accurate tumor staging.
Thus, the introduction of prostate-specific membrane antigen (PSMA) in diagnosis and treatment of PC is a highly
interesting development in radiation oncology of urologic tumors. The present work is to evaluate the integration
of 68Ga-PSMA-PET imaging into standard radiation planning of primary definitive treatment of PC and to determine
the impact of PSMA imaging on tumor staging.
Methods: The data of 15 patients treated for PC between August 2013 and April 2015 were evaluated. Treatment
planning included 68Ga-PSMA-PET imaging. We analyzed whether the use of PSMA-imaging led to a change of the
TNM stage and if it influenced the RT treatment approach or the target volume, due to changes in the gross tumor
volume (GTV) or clinical target volume (CTV), in the final treatment plan.
Results: In 53.3 % of the analyzed patients a change occurred in the TNM stage based on 68Ga-PSMA-PET
examination. The RT concept changed in 33.3 % of all patients, leading to relevant changes in the planning target
volume. Among these, an additional irradiation of the pelvic lymph drainage due to tracer uptake in lymph nodes
was performed in 25 %. Furthermore, boost volumes of PET-positive lymph nodes were added in 80 % of these
cases. A down staging due to the 68Ga-PSMA-PET examination occurred in 13.3 % of all cases.
Conclusions: The integration of 68Ga-PSMA-PET-imaging into the RT treatment planning process can be useful for
detailed target volume planning. The performance of a 68Ga-PSMA-PET frequently leads to changes in the TNM
stage, altering the RT treatment regimen and the target volume. A prospective trial is underway to evaluate the
impact of 68Ga-PSMA-PET based treatment planning on outcome.
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Background
Prostate cancer (PC) is the most common tumor entity
in males in many developed countries [1]. Almost
65.000 patients were newly diagnosed with PC in
Germany alone in 2011 and every year over 10.000 die
from it [2]. There are several treatment options for local-
ized PC, among them radiation therapy (RT), which may
be administered alone or in combination with hormonal
therapy [3]. Definitive RT for PC relies primarily on ac-
curate clinical and radiological tumor staging. To differ-
entiate between local, regional, or systemic disease,
initial staging provides the basis for further treatment
decisions and enables risk group-adapted treatment. On
the one hand staging is of paramount importance to in-
crease the curative chance of patients and on the other
to spare them from unnecessary toxicities. Several im-
aging modalities are used for staging PC such as CT,
MRI or bone scintigraphy. Nuclear medicine methods
include radioactive marked tracers such as Choline-PET
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imaging, each limited by a low specificity. PSMA-PET-
imaging has been shown to be more sensitive as well as
specific for PC staging [4–6].
Prostate-specific membrane antigen (PSMA) is a cell
surface protein with high expression in PC cells [7]. At
lower levels it is expressed within various organs such
as salivary gland tissues and kidneys, and less so in liver,
spleen, bowel and healthy prostate structures [8–10].
On the surface of PC cells it has been shown to be a
thousand-fold increased compared to the other men-
tioned tissues [7]. In 2012, 68Ga-PSMA was developed
as a novel PSMA-ligand and very recent studies show
promising results for its usefulness in recurrent prostate
cancer or as a staging tool [5, 9, 11]. Its introduction in
diagnosis as well as treatment of PC is one of the most
interesting developments in radiation oncology of uro-
logic tumors.
However, the implementation of 68Ga-PSMA-PET-im-
aging in clinical routine is still only available in a few
centers worldwide. Few data is available, especially on
the value for staging and the impact on stage adaption
during treatment planning for RT. The present work is
to evaluate the integration of 68Ga-PSMA-PET-imaging
into standard radiation planning of a primary definitive
treatment of PC and to determine the influence on sta-
ging and on changes in the initially planned treatment
concept for definitive RT in PC.
Methods
Between August 2013 and April 2015, 15 patients were
planned for definitive RT of the prostate with treatment
planning based on CT, MRI and 68Ga-PSMA-PET-imaging
at our institution. All patients gave written informed con-
sent for the purpose of anonymized evaluation and publi-
cation of their data. All reported investigations were
conducted in accordance with the Helsinki Declaration
and with national regulations. The retrospective analysis
was approved by the Ethics Committee of the Technical
University Munich (permit 5665/13).
68Ga-PSMA-PET-imaging was regularly CT based. In
one case (patient #3) MRI was selected because of better
comparability with preceding images. Pre-treatment
68Ga-PSMA-PET CT or MRI was performed between
June 2013 and October 2014 in the staging process. Pa-
tient characteristics are shown in Table 1. The procedure
of elaboration and application of the 68Ga-PSMA-ligand
complex has been described previously [12–14].
All cases were discussed in an interdisciplinary panel
of experienced radiation oncologists, radiologists, nu-
clear medicine physicians and urologists and treatment
decisions were taken on consensus. Based on histo-
pathological Gleason scores, pre-treatment PSA levels and
clinical staging patients were assigned to risk groups (low,
intermediate and high risk) according to the 2014
National Comprehensive Cancer Network guidelines on
prostate cancer [15].
Retrospectively initial pre-68Ga-PSMA-PET tumor stages
were classified according to the 2010 version AJCC/UICC
staging system - including Gleason score, initial PSA levels,
TNM stage, as well as a calculation of the Roach formula
(risk of lymph node involvement [%] = 2/3 (PSA) + (GS-6) ×
10) [16]. According to internal standard operation proce-
dures of our department and following international guide-
lines, initial treatment decisions were made without the
information obtained by 68Ga-PSMA-PET imaging based
on CT/MRI as well as histo-pathological information avail-
able including PSA-level [3, 17]. After PSMA-imaging, all
information was reviewed and re-classification was
performed with the additional information taken into
account. We evaluated the number of cases in which the
information obtained by 68Ga-PSMA-PET imaging led to a
change in staging and subsequently resulted in a change of
the RT concept, such as additional irradiation of the lymph
node regions or local dose escalations.
For treatment planning, CT scans with 3 mm slice
thickness at full bladder and empty rectum were per-
formed. For all patients presenting tumor stages cT1-
cT3a the CTV definition included the prostate and the
base of the seminal vesicles. For patients in stadium
cT3b the seminal vesicles were included completely in
the CTV. To obtain the PTV of the prostate 7 mm were
added to the CTV in all directions. Patients with actual
lymph node involvement (cN+) or an increased risk of
an involvement (risk more than 20 % according to the
Roach formula) received an irradiation of the pelvic
lymph nodes. We defined the corresponding PTV of the
lymph nodes, including the obturatory, internal and
Table 1 Patients´ characteristics
Median Age (years, range) 74 (59–82)
Gleason Score n (%)
Low risk (≤6) 5 (33.3)
Intermediate risk (7) 4 (26.7)
High risk (>7) 6 (40.0)
Serum PSA (ng/ml) n (%)
Low risk (≤10) 7 (46.7)
Intermediate risk (10–20) 3 (20.0)
High risk (>20) 5 (33.3)
Initial tumor stage
(clinical examination and CT/MRI), n (%)
Biopsy T1c 7 (46.7)
Intermediate risk (T2b) 1 (6.7)
High risk (≥T2c) 7 (46.7)
Gleason score, PSA levels and Tumor stage risk group assignment according to
the 2014 National Comprehensive Cancer Network guidelines on prostate
cancer
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external iliac, common iliac and presacral (down to S3)
lymph nodes, with a 5 mm margin [18]. If patients
showed an increased uptake in 68Ga-PSMA-PET in de-
fined lymph nodes, a simultaneously integrated boost
was performed to the enhancement. The PTV of the
suspected lymph node included the morphological cor-
relate of the enhanced lymph node increased by at least
5 mm.
All patients received an intensity-modulated radiother-
apy (IMRT): eight patients were treated with Tomother-
apy® (Accuray, USA) and seven patients received an
IMRT in RapidArc® technique by Varian, USA. The
treatment was performed with full bladder and empty
rectum under daily image guidance (IGRT).
Results
A total of 15 patients were included into the present
analyses. Data on imaging and on treatment decisions
was followed prospectively through collaboration be-
tween the Departments of Nuclear Medicine, Urology
and Radiation Oncology. Table 2 illustrates all tumor
stages of enrolled patients; initial as well as after 68Ga-
PSMA imaging. In 8 out of 15 patients (53.3 %) of all
analyzed patients a change occurred in the TNM
stadium due to the performed 68Ga-PSMA-PET exami-
nation. In 13 out of 15 patients (86.7 %) anti-hormonal
treatment was given either before RT (80 %) or concur-
rently (6.7 %).
Down-staging
Down-staging occurred in 2 cases (13.3 %). Those two cases
were the only ones to receive a previous 11C-Choline-PET-
CT. Radiologically positive lymph nodes were described
on 11C-Choline-PET-CT, but did not show enhancement
in the 68Ga-PSMA-PET scan and were therefore judged as
not suspicious. In one patient (#1, Fig. 1a, b) multiple
paraaortal and iliacal lymph nodes showed a strong uptake
and morphological correlates in the previous Choline-
PET-CT examination. In the 68Ga-PSMA-PET-CT, which
was performed for clarification purposes, none of the
nodes showed tracer accumulation. Thus, it was assumed
that the disease was locally limited and the RT volume de-
lineation included only the prostate. In another patient
(#10), one particularly suspicious preacetabular located
lymph node was identified among a few others that
showed enhancement in a Choline-PET-CT. In the follow-
ing 68Ga-PSMA-PET-CT imaging, no evidence at all was
seen for lymph node involvement.
Up-staging
Up-staging was seen in 6 patients (40 %). In 2 cases the T
stadium had to be corrected, and in another 4 patients a
strong tracer uptake in initially unsuspicious lymph nodes
was seen. To illustrate this, we shall highlight two cases. In
the first case, Patient #2 had a primary tumor which was
detected by MRI, but also showed a questionable extra
capsular spread. The radiology colleagues described it









(CT = 1, MRI = 2,
Choline-PET = 3)
cTNM without PSMA-PET cTNM including PSMA-PET
T N M T N M
1 6 19.1 13 1, 2, 3 1c 1 0 1c 0 0
2 7 8.5 16 1,2 3a 0 0 3b 0 0
3 8 9.6 26 1,2 2c X 0 2c 1 0
4 6 39.6 26 1,2 3b 0 0 3b 1 0
5 9 34.2 53 1 1c 0 0 2b 0 0
6 6 8.2 6 1,2 2c 0 0 2c 0 0
7 7 36 34 1,2 3a 0 0 3a 1 1a
8 6 10.8 7 1 1c 0 0 2a 0 0
9 7 23 25 1,2 3b 0 0 3b 0 0
10 8 9.4 26 1,2,3 2c 1 0 2c 0 0
11 8 13.5 29 1 2b 0 0 3b 0 0
12 7 8.7 16 1,2 1c 0 0 2a 0 0
13 6 63.9 43 1 1c 0 0 2c 0 0
14 9 9.6 36 1,2 1c 0 0 2c 0 0
15 8 23 35 1, 2 1c X X 2c 1 Xb
Shown are biopsy Gleason score, maximum PSA level before treatment and calculation of lymph node involvement following the Roach formula, as well as evolvement
of tumor stages before and after PSMA-PET imaging (changes are in bold). aM1 based on para-aortal lymph nodes. bPSMA uptake in the 5th rib right, without CT
morphologic correlation, suggesting possible bone metastasis
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as rather atypical for the tumor. Later a 68Ga-PSMA-
PET-CT examination confirmed the extra capsular tumor
spread on the dorsal right side with additional infiltration
of the seminal vesicles. In this case the T stage evolved
from cT3a to a cT3b (Fig. 2a, b).
In the second case, neither MRI nor CT found any in-
dication of lymph node metastases in patient #4, but
after 68Ga-PSMA-PET-CT examination of one pararectal
left lymph node, another presacral right (Fig. 3a, b), and
several others along the iliacal vessels, a pronounced
tracer uptake was shown. Without the positive lymph
nodes seen in the PET examination, the pelvic lymphatic
drainage would have been irradiated due to the risk of
lymph node involvement of 26 % according to the Roach
formula. Including the newly obtained information the
affected lymph nodes were treated with a higher radi-
ation dose (54 à 2.17 Gy as a simultaneously integrated
boost) than the surrounding pelvic lymphatics (45 à
1.8 Gy). The treatment plan is illustrated in Fig. 4a. The
primary tumor within the prostate received no higher
dose and the whole prostate plus seminal vesicles were
treated to a total dose of 74 Gy.
No change of stage
Seven patients (46.7 %) experienced no change of stage.
This also included those cases where the biopsy con-
firmation (T1c) evolved to any other T-stage based on
image modalities.
As shown in Table 3, advanced tumors with initially
higher T-stages have an increased risk of upstaging by
68Ga-PSMA imaging. On the other hand small tumors
(lower T-stages) were more likely to experience down-
staging through 68Ga-PSMA-PET.
Similarly, the Gleason score seemed to influence the
likelihood of a tumor up-staging. With a Gleason score of
7 or under, only 1 patient (6.7 %) experienced a further
up-staging. For scores of 7 or over, 2 (13.3 %) and respect-
ively 3 (20 %) cases had to be grouped into a higher TNM
stadium. Down-staging worked up for Gleason score was
balanced for patients with scores over and lower than 7.
Concerning PSA levels the trend seemed to be less con-
vincing. The six up-stagings were spread out over three
groups. 3 cases were found for PSA levels under 10 ng/ml
and one case for PSA levels between 10 and 20 ng/ml. 2
cases occurred in patients having initial PSA levels over
a b 
Fig. 1 Down-staging by 68Ga-PSMA-PET. Choline-PET-CT (a) with elevated tracer uptake of left iliac lymph node. 68Ga-PSMA-PET (b) does not
confirm the questionable involvement seen by Choline-PET-CT
a b 
Fig. 2 Up-staging due to extra capsular spread by 68Ga-PSMA-PET. Questionable extra capsular spread on MRI (a). In 68Ga-PSMA-PET imaging (b)
is strong tracer uptake in the bladder and dorsal, as indicated by the arrow, in the extra capsular region, suggesting a strong possibility of
its involvement
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20 ng/ml. Nevertheless, down-staging was seen in 2 pa-
tients with PSA levels under 20 ng/ml, as seen in Table 4.
The radiotherapy concept was changed in 33.3 % of the
patients analyzed. This produced relevant changes in the
gross tumor volume and clinical target volume. Among
these changes an additional irradiation of the pelvic lymph
drainage due to tracer uptake in lymph nodes was per-
formed in 25 %. Furthermore, boost volumes on positive
lymph nodes detected by 68Ga-PSMA-PET were added in
80 % of these cases (Fig. 4a and b).
b a 
Fig. 3 Up-staging due to lymph node involvement by 68Ga-PSMA-PET. Non-suspicious lymph nodes on MRI (a) presacral. In 68Ga-PSMA-PET
imaging (b), the lymph node displays enhancement and was thus treated with a higher radiation dose
b a 
Fig. 4 Treatment plan comparison. Basic treatment plan (a), including lymph node irradiation up to 45 Gy à 1.8 Gy. Based on the information
obtained by 68Ga-PSMA-PET imaging, PET-positive nodes receive a simultaneous integrated boost to 54 Gy à 2.17 Gy. In comparison with Fig. 4a
an example of the dose distribution (b) without the knowledge through the 68Ga-PSMA-PET; the lymph node involvement would not have been
suspected and therefore only the prostate itself would have been treated
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Discussion
68Ga-PSMA-PET has shown high diagnostic accuracy
for patients with PC. The data from the present manu-
script show that 68Ga-PSMA-PET imaging had a huge
impact on staging. Thus, compared to standard imaging
based on pathological parameters, PSA values and im-
aging with CT and/or MRI only, a substantial impact on
tumor staging and re-staging can be expected based on
68Ga-PSMA-PET imaging. Since in definitive RT for PC
precise delineation of involved tissue as well as tissue at
risk is necessary, and since there is a clear benefit of
dose escalations to involved tissue, the diagnostic value
of 68Ga-PSMA PET is evident.
Recently, the usefulness and accuracy of 68Ga-PSMA-
PET imaging has been described increasingly in the re-
current setting of PC [5, 11, 19, 20]. For example, Eiber
et al. [5] attested significantly higher detection rates of
PC and lymph nodes as previously reported for other
imaging modalities. This particularly applied in the
range of low PSA-levels (<0.5 ng/mL). In 33 % of cases,
the tumor site was exclusively detected by 68Ga-PSMA-
PET examination. An additional 25 % of the patients
showed lesions that were not detectable by CT. In total,
over 50 % of crucial information was identified by 68Ga-
PSMA-PET for final diagnosis, as well as staging and
treatment decisions. The specificity of 68Ga-PSMA-PET
has been demonstrated by the use of PSMA-radioguided
surgery as well as for lymph node staging in primary PC
[21, 22]. With the radiotherapy concept changing in a
third of all patients we assume that a better sensitivity
and specificity may lead to improved radiotherapy con-
cepts in patients having received a 68Ga-PSMA-PET.
All 68Ga-PSMA PET examinations were performed for
treatment planning on the premises of 68Ga-PSMA-PET
imaging as a “gold standard”. For precise diagnosis, cor-
relation with pathological analyzes is necessary. This is
currently being done for the diagnostic value of lymph
node identification within a prospective trial at our insti-
tution. Though more data is still needed to verify sensi-
tivity and specificity of the 68Ga-PSMA-PET, promising
studies have been conducted. A current study by Maurer
et al. [23] showed for primary patients before radical
prostatectomy and patients who underwent surgery for
lymph node metastases a high histo-pathologically
proven sensitivity (75 and 65.9 %) and specificity (98.8
and 98.9 %). CT or MRI imaging sensitivity (41.7 and
43.9 %) and specificity (85.5 and 85.4 %) was clearly
lower. Another recent study by Giesel et al. confirms
these findings [24].
It should also be mentioned that PSMA-negative PC
seems to be rare, but false negative cases have been
reported in the literature [8, 20, 25]. Whether this
approach is correct will be verified by long-term PSA-
levels. At our institution PSA-levels are monitored every
3 months after radiation therapy.
Nevertheless, in previous studies other imaging modal-
ities such as CT and MRI showed similar performances
in PC nodal staging by indirectly assessing nodal inva-
sion measuring lymph node diameter. Consequently,
their sensitivity was proven to be low. Using a 10 mm
threshold, the sensitivity was reported to be less than
40 % [26]. Functional PET imaging, mostly using
radiolabeled-choline derivatives, are of limited value and
often underestimate the extent of metastatic spread [27].
Evangelista et al. [28] evaluated, in a big meta-analysis, a
high specificity for 11C-Choline-PET CT of 95 % in pri-
mary lymph node staging but a low sensitivity of just
50 %. Husarik et al. [29] found a sensitivity to detect re-
current disease of 86 % and described these results as ra-
ther discouraging, especially in terms of its inability to
detect small metastases - recurrent disease was reliably
diagnosed in patients with PSA levels of >2 ng/ml. In
another study Choline-PET-CT was found to be statis-
tically significantly inferior when compared to 68Ga-
PSMA-PET-CT in a recurrent setting as described by
Afshar-Oromieh et al. [24].
Interestingly, there have been studies that support the
theory that detection rates increase parallel with elevated
PSA levels [30]. In a primary setting a tailored treatment
approach is very important, and with mostly consider-
ably elevated PSA levels, 68Ga-PSMA-PET imaging
could prove to be overly effective. Here, the measure-
ment of PSA level alone can at best calculate the risk of
Table 3 Distribution of prostate cancer T stage before and after



















Biopsy T1c 6 (40.0) 1 (6.7) 1 (6.7) 0
Low risk (≤T2a) 0 0 0 2 (13.3)
Intermediate
risk (T2b)
2 (13.3) 1 (6.7) 0 1 (6.7)
High risk (≥T2c) 7 (46.7) 4 (26.7) 1 (6.7) 12 (80.0)
Table 4 Dependence on Gleason Score and PSA serum levels





Gleason score <7 5 1 (6.7) 1 (6.7)
Gleason score 7 4 2 (13.3) 0
Gleason score > 7 6 3 (20.0) 1 (6.7)
PSA level <10 ng/ml 7 3 (20.0) 1 (6.7)
PSA level 10–20 ng/ml 3 1 (6.7) 1 (6.7)
PSA level >20 ng/ml 5 2 (13.3) 0
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lymph node metastases by using the Roach formula [16].
On a similar note, it has been noted that there is higher
expression in lesions with higher Gleason scores [5, 31].
The Gleason score as well as PSA levels were also taken
into account in our study.
One main limitation of this analysis is its small patient
number. However, since no data are currently available
and 68Ga-PSMA-PET imaging is performed at several cen-
ters, the results provide a useful basis for decision-making
in radiation oncology. Additionally, the homogenous re-
sults in the present “typical“ PC patient population under-
line the reliability of the reported data. It is important to
note that in patients with higher T-stages, as well as higher
PSA-values, the impact of 68Ga-PSMA-PET is larger on
restating than in other tumor stages, meaning that in those
patients a larger amount of up-stagings were observed
than for lower tumor stages.
However, other factors such as anti-hormonal treatment
might influence staging changes and therefore represent
limitations to our study. In both of the down-staging cases
anti-hormonal treatment was given either at the time or
before 68Ga-PSMA imaging. These factors possibly had an
effect on PSMA-image enhancement and subsequent down-
staging. In contrast, Afshar-Oromieh et al. [11] showed that
patients taking anti-hormonal medication at the time of the
68Ga-PSMA-PET examination had more often positive PET
results than patients not receiving hormonal therapy. Also,
in some cases the time span between initial imaging modal-
ities and 68Ga-PSMA-PET was up to a few months (max-
imum of 3 months - e.g. due to bridging anti-hormonal
treatment). Therefore the possibility cannot be excluded that
tumor stages in a few cases not only evolved because of the
diagnostic tool, but also simply because of time.
In summary, we see great potential for 68Ga-PSMA-PET
imaging. On one hand, in the case of down-staging, pa-
tients are potentially spared from unnecessary toxicities to
surrounding tissues due to smaller radiation fields. For ex-
ample, radiation doses could be drastically reduced by only
treating lymphatic drainage if pelvic enhancements are ob-
tained by 68Ga-PSMA-PETand not based on the calculated
lymph node risk according to the Roach formula. In order
to standardize this procedure at least PSA-long-term ob-
servations have to be conducted. On the other hand, in
the case of up-staging, enlarged radiation volumes were
its consequence and additional radiation dose (boost) to
affected lymph nodes or within the prostate region could
potentially translate into improved local control and/or
overall survival for our patients. This will be evaluated
within a prospective clinical trial at our institution.
Conclusions
The integration of 68Ga-PSMA-PET imaging into RT
treatment planning can be a powerful tool and useful
method for detailed target volume delineation. In addition
to the indication for PSA persistence after radical prosta-
tectomy or PSA relapse without image morphological cor-
relate, a 68Ga-PSMA-PET can also be advantageous for
radiation treatment planning in primary PC. Assuming
68Ga-PSMA-PET as “gold standard” we showed in this ini-
tial patient series that the implementation of 68Ga-PSMA
-PET hybrid imaging frequently led to changes in the
TNM staging and consequently influences the radiothera-
peutic treatment regimen as well as the clinical target
volumes. This yields the possibility for boost volumes
directed to PET-positive areas. Whether this will be
reflected by an improvement in survival rates needs to be
investigated in larger prospective studies.
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